

Original article for the section Discoveries in MBE

TRANSMISSION BETWEEN ARCHAIC AND MODERN HUMAN ANCESTORS DURING THE EVOLUTION OF THE ONCOGENIC HUMAN PAPILLOMAVIRUS 16

Ville N. Pimenoff ^{a,b*}, Cristina Mendes de Oliveira ^{a,c}, Ignacio G. Bravo ^{a,d}

^aInfections and Cancer Laboratory, Cancer Epidemiology Research Programme, Catalan Institute of Oncology, Barcelona (Spain); ^bUnit of Biomarkers and Susceptibility, Bellvitge Institute of Biomedical Research (IDIBELL), Barcelona (Spain); ^cVirology Laboratory, Institute of Tropical Medicine, University of São Paulo (Brazil); ^dMIVEGEC (UMR CNRS 5290, IRD 224, UM), National Center for Scientific Research (CNRS), Montpellier (France).

Short Title: Origin, evolution and dispersal of HPV16.

Keywords: human papillomavirus, virus-host coevolution, sexually transmitted infection, infection and cancer, evolutionary medicine, host-switch, variant, Hominin evolution, divergence.

***Corresponding author:**

Ville N. Pimenoff PhD
Infections and Cancer Laboratory | Unit of Biomarkers and Susceptibility
Catalan Institute of Oncology, Gran Via de l'Hospitalet, 199
08908 L'Hospitalet de Llobregat
Barcelona – Spain
Tel +34 93 260 7812. Ext: 3320
ville.pimenoff@gmail.com

ABSTRACT (250 words)

Every human suffers through life a number of papillomaviruses (PVs) infections, most of them asymptomatic. A notable exception are persistent infections by *Human Papillomavirus 16* (HPV16), the most oncogenic infectious agent for humans and responsible for most infection-driven anogenital cancers. Oncogenic potential is not homogeneous among HPV16 lineages, and genetic variation within HPV16 exhibits some geographic structure. However, an in-depth analysis of the HPV16 evolutionary history is still wanting.

We have analysed extant HPV16 diversity and compared the evolutionary and phylogeographical patterns of humans and of HPV16. We show that codivergence with modern humans explains at most 30% of the present viral geographical distribution. The most explanatory scenario suggests that ancestral HPV16 already infected ancestral human populations, and that viral lineages co-diverged with the hosts in parallel with the split between archaic Neanderthal-Denisovans and ancestral modern human populations, generating the ancestral HPV16A and HPV16BCD viral lineages, respectively.

We propose that after out-of-Africa migration of modern human ancestors, sexual transmission between human populations introduced HPV16A into modern human ancestor populations. We hypothesise that differential coevolution of HPV16 lineages with different but closely related ancestral human populations and subsequent host-switch events in parallel with introgression of archaic alleles into the genomes of modern human ancestors may be largely responsible for the present-day differential prevalence and association with cancers for HPV16 variants.

INTRODUCTION

Virus lifestyle shapes viral population structure through essential virus life traits, such as infectivity, immunogenicity, latency, transmission rate, mutation rate, virion productivity and duration of the infection (Sharp 2002). The interaction between the virus and the host's immune system strongly influences viral evolution: immune memory reduces the number of susceptible hosts, and differential immune recognition and response against different pathogen phenotypes may favour selection of certain viral lineages (Holmes 2008). Finally, the evolutionary history of the host constrains further the population structure of the virus. Thus, for viruses and hosts with a long shared evolutionary history, the virus population is shaped by population-level processes of genetic drift and natural selection, in both the virus and the host populations (Holmes 2008).

Papillomaviruses (PVs) have a long common history with amniotes (Bravo and Félez-Sánchez, 2015). PVs are double-stranded DNA viruses, with a circular genome of about 8kb. More than 300 PVs have been described and above 200 of them have been retrieved from humans (Bzhalava et al. 2015). Human papillomaviruses (HPVs) infect dividing epithelia, and virtually all humans are hosts to a variable number of HPVs infections at cutaneous (Antonsson et al. 2003) but often also at mucosal sites (Ma et al. 2014). The viral infection does not kill the target cell and in most cases PVs can complete their life cycle and be maintained as a chronic, asymptomatic infection with viral genomes remaining episomally as plasmids in the infected cell (Doorbar et al. 2012). In some cases they can cause productive, wart-like lesions or even be involved in certain cancers (Doorbar et al. 2012). The fine balance between viral replication and host immune tolerance suggests a long coexistence between PVs and their hosts, and indeed ancestral PVs probably infected the ancestral amniotes (García-Vallvé et al. 2005) and possibly all bony vertebrates (López-Bueno et al. 2016). The evolution of PVs in mammals likely started with an initial adaptive radiation event, that generated a handful of viral crown groups, linked to the evolution of mammalian fur and skin glands (Bravo and Félez-Sánchez, 2015; Gottschling et al., 2011). This diversification was followed by limited host-linked evolution and encompassed also incomplete lineage sorting and host-switch events (Gottschling et al. 2007; Gottschling et al. 2011). At shallower evolutionary timescale, it has been commonly assumed that HPV16 has co-diverged with modern human populations, based on certain geographical structure of HPV16 variant distribution (Bernard 1994; Cornet et al. 2012), but this hypothesis has never been rigorously tested.

Infections by anogenital HPVs are very common: above 80% of all sexually active adults are infected by one of these HPVs at least once in their lifetime (Einstein et al. 2009; Chesson et al.

2014), and the time point prevalence of cervical HPVs infections in sexually active healthy women is estimated around 12% (Bruni et al. 2010) or even higher in younger women (Molden et al. 2016). At least twelve evolutionarily-related HPVs are carcinogenic to humans (Bouvard et al. 2009), causing different fractions of anogenital and oropharyngeal cancers (Moscicki et al. 2012). HPV16 is the most prevalent HPV in infection-associated cancers of the cervix, vulva, vagina, anus, penis and oropharynx (Moscicki et al. 2012), but it is also the most prevalent HPV infection of the genital tract occurring asymptotically in healthy individuals (Bruni et al. 2010). Within the HPV16 lineage, distribution of genetic diversity presents certain geographic structure, with different HPV16 variants showing differential prevalence in different geographical regions (Cornet et al. 2012). Furthermore, the oncogenic potential is not homogeneous for all HPV16 variants (Schiffman et al. 2010), and varies in association with different human populations (Villa et al. 2000; Berumen et al. 2001; Burk et al. 2003; Xi et al. 2006; Zuna et al. 2011; Cornet et al. 2013). Such differential connection between viral phylogeography and oncogenic potential might indicate that the evolution of HPV16 lineage has been at least partly shaped by the differential host immune response.

In this study we have analysed human and virus genomic data to infer the evolutionary history of HPV16. The common understanding about the evolution of HPVs is that the modern repertoire of diverse HPVs has coevolved with modern humans as a host population, so that the current geographic distribution of HPVs reflects modern human migration dispersal patterns (Ho et al. 1993; Bernard 1994). Here, we show for the first time that differential coevolution of HPV16 lineages with different but closely related ancestral human populations together with recent host-switch events may be largely responsible for the present-day differential prevalence and association with cancers for HPV16 variants. The most parsimonious interpretation of our results requires that the ancestor of HPV16 already infected the ancestral human populations more than 500 thousands years ago (kyr). The split between Neanderthals/Denisovans and modern human ancestor populations was mirrored by a split in the viral populations, namely HPV16A, carried by ancestral human populations, and HPV16BCD, carried by the populations of modern human ancestors in Africa. After the last Out-of-Africa migration event 60-120 kyr, the modern human ancestor populations that left Africa carried a reduced sample of the viral diversity in the continent: the HPV16B lineage remained in African populations but was lost by lineage sorting in those leaving the continent. The viral lineage HPV16CD gave rise in allopatry to the HPV16C variant in Africa and to the HPV16D variant outside Africa. Later, the interbreeding events between Neanderthal and Denisovan populations with modern human ancestor populations lead to a host-switch

through sexual transmission of the HPV16A virus lineage from archaic populations into the modern human ancestors. The HPV16A lineage thus transmitted expanded rapidly in the new host populations and became dominant in Eurasia and in the Americas.

RESULTS

HPV16 Phylogeography

We inferred the phylogenetic relationship among all available, non-recombinant HPV16 genomes (N=118) under maximum likelihood (ML) framework for both the full-genome alignment (supplementary data S1, supplementary material online) and for the coding region alignment (supplementary data S2, see also supplementary table S1, supplementary material online). Phylogenetic inference recovered all previously reported HPV16 variant lineages, and we retained for subsequent analysis HPV16A1-3, A4, B, C and D lineages, all supported by more than 98% bootstrap values for the full genome alignment (fig. 1A and supplementary fig. S1, supplementary material online). Pairwise distances under ML were significantly larger (2.28 times, 95% CI 1.88-2.69; Wilcoxon-Mann-Whitney test p -value= 2.2e-16) for the full genome than for the selection-filtered alignment (supplementary fig. S2, supplementary material online).

To assess HPV16 phylogeography, we analysed a total of 1719 HPV16 isolate cases (alignments available as supplementary data S3-S4, supplementary material online) by complementing the 118 HPV16 full genome sequences with 1601 partial HPV16 isolate sequences spanning the LCR, the *E6* oncogene, and the *L2* capsid gene. A total of 1680 global HPV16 isolate sequences with known geographical origin could be unambiguously assigned to a precise HPV16 lineage using an evolutionary placement algorithm (supplementary table S2, supplementary material online). Phylogeography of the 1680 isolate cases showed that the HPV16A1-3 lineage predominated in Europe, South Asia and Central/South America, and was also present in all other continental subgroups, albeit with very low prevalence in sub-Saharan Africa (fig. 2). HPV16A4 was the most prevalent lineage in East Asia and was also present in North America, but was virtually absent elsewhere. Variants B and C were largely restricted to Africa and were especially prevalent in Sub-Saharan Africa, although they were also observed in North America. Variant D was present in all continents, displaying low prevalence in Sub-Saharan Africa, and the highest frequency in Central/South America.

To explain the evolution and diversity of HPV16 and to infer its origins, we explored the differential fit to the data of two alternative scenarios: i) the *recent-Out-of-Africa* (ROOA) model of exclusive codivergence for HPV16 with modern human populations, and ii) the *Hominin-host-switch* (HHS) model, including a viral transmission between archaic and ancestral modern human populations. On the one hand, the ROOA scenario required exclusive codivergence of HPV16 lineages with modern human dispersals. On the other hand, the HHS scenario implied an ancestral virus-host codivergence episode during the split between *H. sapiens* and *H. neanderthalensis* lineages, followed by more recent transmission events between Neanderthals/Denisovans and modern human ancestors (fig. 3). Both scenarios are plausible given the topology of the phylogenetic relationships between HPV16 lineages (fig. 1) and the impossibility to root the HPV16 tree using extant HPVs sequences.

To test the explanatory power of the ROOA model, we analyzed the correlation between geography-based population structure of modern humans and of HPV16 by comparing genetic distances between geographically defined human metapopulations with the genetic distances between HPV16 isolates. We used nine previously described metapopulation groups (supplementary table S3, supplementary material online), excluding North America due to lack of human genome data, and tested the correlation between the F_{ST} distance matrices for humans and for HPV16 (supplementary fig. S3, supplementary material online). We observed indeed correlation between both matrices, but geographical structure across different human genome loci explained less than 30% of the worldwide HPV16 geographical structure (table 1, see also supplementary table S4, supplementary material online). Notably, most of the European and sub-Saharan African ascertained autosomal human genome loci variability showed significant but limited (<30%) correlation with the HPV16 LCR-E6 variability. Very interestingly, after excluding the sites under selection in the HPV16 E6 gene only the correlation with the mitochondrial genome variability and most of the sub-Saharan African but not European ascertained autosomal genome data remained significant, and accounted for barely 15% of the global distribution of HPV16 diversity. Nevertheless, it is important to note that after controlling for false discovery rate none of the human genome and of HPV16 correlations showed to be significant.

Time inference for HPV16 diversification

To estimate divergence times for HPV16 diversification under the two alternative evolutionary scenarios, we applied a Bayesian Monte Carlo Markov Chain (MCMC) inference. First, we

tested whether we could accurately identify the root of the HPV16 genome diversity by performing phylogenetic inference incorporating the most closely related HPVs, members of *Alphapapillomaviruses* species 9. The long evolutionary distances between these viruses and HPV16 prevented unambiguous identification of the root of HPV16 lineages, with either ML (RAxML) or Bayesian (Phylobayes) approaches (supplementary fig. S4, supplementary material online). In all reconstructions the preferred topology was (A,(B,(C,D))), which corresponded to the HHS scenario. Nevertheless, the likelihood values for the HPV16 trees obtained after forcing our two alternative scenarios, namely the HHS and ROOA models, differed by less than 0.01%, and neither the Shimodaira-Hasegawa test nor the Robinson-Foulds split method showed significant differences between both topologies. When introducing time into the Bayesian (BEAST) phylogenetic analyses without imposing any prior on tree topology, the same (A,(B,(C,D))) topology (*i.e.* the HHS model) was systematically the preferred one for both HPV16 complete and HPV16 selection-filtered coding region alignments (fig. S4). The combined difference in topology and branch length between trees obtained with the full-length and with the selection-filtered alignments was very small (as assessed by a K-score < 0.004) (supplementary table S5, supplementary material online). We resorted then to dated Bayesian MCMC inference for identifying the more plausible between the two alternative evolutionary scenarios. For the *HHS* scenario we used the archaic *Hominin* divergence at 500kya (95% confidence interval 400 – 600kya, see references in materials and methods) to calibrate the time for the most recent common ancestor (tmrca) of extant HPV16 lineages, as well as the recent modern human migration out-of-Africa at 90kya (95% confidence interval 60 – 120kya, see references in materials and methods) to calibrate the tmrca of lineages HPV16C and D. For the *ROOA* scenario we used the recent migration out-of-Africa with the same 90kya settings as above but in this case to calibrate the tmrca of all HPV16 lineages. Both strict and relaxed clock were tested for all MCMC calibrations and the best log-likelihood value using Bayes Factor ($2\ln BF$) was obtained for relaxed clock ($2\ln BF > 38$). The demographic models of exponential growth or of Bayesian skyline for the population function of the coalescent tree prior yielded in both cases growth rates consistently above zero, excluding thus constant population size as a model. In addition, Bayesian skyline plot estimating changes in effective population size through time showed a significant increase of the HPV16 population in the last 12kya (supplementary fig. S5, supplementary material online). For final analyses we used the evolutionary models and priors showing the best performance, namely relaxed log-normal molecular clock and a Bayesian skyline coalescent model ($2\ln BF > 83$). Comparison of divergence time estimates between the *HHS* and *ROOA* scenarios for HPV16 evolution are presented in table 2. For the analyses based on the positions evolving neutrally, the log-

marginal likelihoods showed the highest value and strongest support ($2\ln BF = 8.9$) for the *HHS* scenario with a substitution rate 18.4×10^{-9} [95% CI 14.3×10^{-9} - 22.1×10^{-9}] subs/site/yr. For the analyses that included the positions under selection, the *HHS* model was again the preferred model albeit with a substitution rate two times higher. The log-marginal likelihood value for the *HHS* scenario including the positions under selection did not significantly differ from that for the *ROOA* model ($2\ln BF = 1.2$), although the inferred evolutionary rate in the case of *ROOA* model needed to be around five times higher. Maximum clade credibility tree inferred for selection-filtered HPV16 genome coding region alignment under the *HHS* scenario and enforcing the two *HHS* model time point calibrations is presented in fig 1B. Furthermore, to estimate whether our time point calibrations had an impact on the divergence time estimates we also performed MCMC analysis either by imposing the *HHS* model topology or without imposing any prior on tree topology and without using any time point calibrations (table 3). Depending on substitution rate priors, divergence times of extant HPV16 lineages showed to be between 260 kya and 4.8 Mya. In all cases, the preferred model was the *HHS* scenario. Although HPV16A was thus always the basal clade, divergence within HPV16A showed to be lower than within HPV16BCD (supplementary fig. S6, supplementary material online).

Variation within the HPV16 E6 oncogene

To investigate geographical differences in HPV16 genetic diversity, we estimated summary statistics within each geographic HPV16 population using all 1123 available HPV16 nearly complete *E6* sequences (table 4). Overall, HPV16 *E6* genetic diversity was highest outside sub-Saharan Africa. Both Tajima's D and Fu's-Li's D statistics as well as the more robust R2 index showed statistically large negative values for European isolates, suggesting past selective sweeps and/or population expansion, for HPV16 population in Europe only. HPV16 *E6* haplotype diversity was similar in sub-Saharan Africa, Europe and South America and significantly higher in North Africa and Central America compared with sub-Saharan Africa (table 4). East Asian and Central American HPV16 isolates showed higher average number of pairwise differences compared with sub-Saharan African isolates, even after accounting for intralineage diversity. Further, to estimate the geographical origin of the HPV16 *E6* gene haplotype diversity we constructed a median-joining haplotype network for the *E6* gene sequences (table 5, see also supplementary fig. S7, supplementary material online). Two of the most common HPV16A1-3 lineage *E6* haplotypes were observed in Eurasian isolate background, and only 1-3% of these common haplotypes originated from sub-Saharan African

isolates). In contrast, the most frequent HPV16B and C variant *E6* haplotypes were observed in more than 92% of African isolate background. The most common HPV16D *E6* haplotype displayed the highest frequency (58%) in the American isolate background and the lowest (4-5%) in North and sub-Saharan African isolates. The second most common HPV16D *E6* haplotype showed the highest frequency (58%) in North African isolates, intermediate frequencies in Eurasian and in American isolates (18% and 21% respectively) and very small (3%) of the sub-Saharan African isolate background.

DISCUSSION

HPV16 is the most oncogenic virus for humans, and epidemiological evidence suggests that its oncogenic potential is associated with high viral loads and with infection persistence (Doorbar et al. 2012; Moscicki et al. 2012). Viral genotypic variation may underlie strong phenotypic variation so that different HPV16 variants may display differential persistence and viral load and therefore differential carcinogenicity. Several reports have communicated differential oncogenic potential for different HPV16 variant lineages (Villa et al. 2000; Schiffman et al. 2010; Zuna et al. 2011; Freitas et al. 2014). However, the differential risks for different variants seem to depend on the host population (Cornet et al., 2013; Qmichou et al., 2013), and to vary with the specific individual genetic background (Xi et al. 2006; Lopera et al. 2014). In the present study we have addressed the origin, diversification and dispersal of HPV16. We have used the largest available collection of HPV16 full-length genomes as well as partial sequences to generate estimates of the worldwide phylogeography and divergence time of extant HPV16 lineages. Our results support a scenario of codivergence of HPV16 with separate but closely related ancestral Hominin populations with subsequent host-switch events, likely through sexual transmission between archaic and modern human ancestral populations in the recent human evolutionary history. We have further compared the genetic diversity patterns of HPV16 with those estimated for modern human populations using genome data. Altogether, our results suggest that virus-host coevolution as well as host switch events have been fundamental factors that have shaped HPV16 evolution.

Purifying selection can mask the ancient origin of recently sampled pathogens (Wertheim and Kosakovsky Pond 2011), and our results point in the same direction. Results based on only HPV16 genome positions evolving neutrally showed significantly better fit to the data for our *HHS* model while analyses including positions under selection still preferred the *HHS* model but

could not differentiate the two alternative scenarios, namely the *ROOA* and the *HHS* model, tested in this study (table 2). More importantly, our MCMC inference showed that irrespective of the evolutionary rate prior used, divergence times for extant HPV16 lineages largely predate the estimated recent out-of-Africa migration of modern human ancestors 60–120kya. Furthermore, although HPV16A is the oldest lineage, the tmrca for the HPV16BCD variants (197kya, 95% 121–291kya) was older than the tmrca for the HPV16A lineage (88kya, 95% HPD 50 – 134kya), and the HPV16A lineage encompasses less genetic diversity than the sister HPV16BCD lineages. Taken together, the lower divergence within HPV16A, the good match for the tmrca of this lineage with the Out-of-Africa migration of modern humans and the delayed expansion of HPV16A reinforce the *HHS* scenario: the exceptional interbreeding events between archaic and modern human populations resulted in a strong bottleneck for the transmission of HPV16A, so that only a small fraction of the HPV16A diversity available in the Neandertal/Denisovan populations underwent effectively a horizontal transfer towards populations of ancestral modern humans.

Mounting evidence suggests that virus-host codivergence is not the only essential driving force for PV evolution. At higher taxonomic levels virus-host co-phylogeny events explain only around 30% of the PV evolutionary history, while additional events of lineage sorting, lineage duplication and host switch have played major roles during the evolution of PVs (Gottschling et al. 2011). In the present study, we have quantified for the first time that codivergence between modern humans and HPV16 explains less than 30% of the current geographical distribution of the viral extant diversity, largely based on the virtual absence of HPV16B and HPV16C lineages outside Africa and on the enrichment of HPV16A and HPV16D outside Africa (fig. 2). The contribution of virus-host codivergence to HPV16 evolution, regardless of excluding the viral coding region sites under selection, showed to be consistent only for mitochondrial genome variability and less consistent using European ascertained autosomal SNPs compared with sub-Saharan African ascertained autosomal SNPs. It is tempting to speculate that this difference in consistency might be partly due to the SNPs introgressed from archaic populations into the genomes of non-African modern humans. However, the underlying biological complexities and limitations of the available data to compare the human genome and of HPV16 genetic diversity restrained us from further estimations of local adaptation between virus and host genomes. Nevertheless, under the *ROOA* scenario, one would have expected a consistently high correlation between human and viral phylogeography. Instead, several lines of evidence argue further against this *ROOA* scenario for HPV16. First, the *HHS* scenario is preferred over *ROOA* in terms of HPV16 lineage phylogeny

(supplementary fig.S6, supplementary material online). Second, the hypothesis of exclusive codivergence of all HPV16 lineages with the ancestral dispersals of modern humans does not explain the largely predominant role of HPV16A (fig. 2), the most basal HPV16 lineage, in all continents and in all indigenous populations, except in sub-Saharan Africa (Cornet et al., 2012; Lopera et al., 2014; Mendoza et al., 2013; Picconi et al., 2003; Qmichou et al., 2013; Tan et al., 2013). Moreover, for indigenous populations in South America, for instance, the increased presence of HPV16A lineage variants has been proposed to reflect the influence of recent European occupation (Picconi et al. 2003). However, such a rapid selective sweep of the putative pre-Columbian HPV16 genetic diversity would require strong selection forces for the viral dynamics in very short time scale, which are not compatible with our current understanding of PV evolution (Bravo and Félez-Sánchez, 2015). Third, the geographical dichotomy for the HPV16 *E6* gene haplotype backgrounds consistently supported our *HHS* model over *ROOA*: most common HPV16A lineage haplotypes were observed mostly in Eurasian populations while most common HPV16B, C and D lineage haplotypes were observed mainly in African populations (table 5). And fourth, while human genetic diversity is highest in sub-Saharan Africa (1000 Genomes Project Consortium et al. 2015) our results of HPV16 *E6* variability showed consistently higher genetic diversity estimates outside sub-Saharan Africa (table 4).

After rejecting the *ROOA* model as explanatory framework for HPV16 evolution, we have explored the *HHS* model as alternative scenario, implying a host switch of an ancestral HPV16 lineage between archaic and modern human ancestral populations (fig. 4). Indeed, recent genomic studies have confirmed the admixture of modern human ancestors with Neanderthals and Denisovans through repeated interbreeding after migration to Europe and Asia, respectively (Lazaridis et al., 2014; Qin and Stoneking, 2015; Reich et al., 2010; Vernot and Akey, 2015). Such interbreeding events lead to adaptive introgression of genetic material from our closest evolutionary relatives into the genome of a subset of modern human ancestors. We propose here that in parallel to the introgression of genetic material, sexual intercourse between Neanderthals/Denisovans and modern human ancestors also prompted sexual transmission of PVs, chiefly of the HPV16A lineage (fig. 4). Our results on HPV16 phylogeography, genetic diversity and tmrca of the different HPV16 lineages sustain this *HHS* scenario, in which the divergence of extant HPV16 lineages (ca. 460kya) predates the recent out-of-Africa migration of modern human ancestors (table 2), and thus, ancestral HPV16 lineages probably already infected the ancestral, closely related Hominin groups. The host split between the ancestral archaic (Neanderthal/Denisovan) and the modern human ancestor

populations was probably mirrored by a viral split resulting in the ancestral HPV16A lineage and of the ancestral HPV16BCD lineage, respectively (fig. 3BC). Among the recurrent out-of-Africa expansions of ancestral Hominin groups, which may have occurred some 460 kya, Neanderthals/Denisovans may have carried essentially the ancestral HPV16A. Evolution of HPV16 genomes in ancestral Hominin populations remaining in Africa, instead, would have lead to HPV16B and CD lineages (fig 4). The virtual absence of HPV16B outside Sub-Saharan Africa is parsimoniously explained if in the last out-of-Africa expansion, the modern human ancestors that left Africa probably lost the ancestral HPV16B lineage by a lineage sorting event (Johnson et al. 2003). Similar pattern of virus extinction after host population bottleneck has been observed in non-human primates (Kapusinszky et al. 2015). After the modern human dispersal, the HPV16CD ancestor generated in allopatry the HPV16C lineage in the populations remaining in Africa, and the HPV16D lineage in the populations outside Africa (fig. 4). During their expansion in Europe and in Asia, modern human ancestors experienced limited admixture with Neanderthal and Denisovan populations, and were exposed to the HPV16A lineage, most likely through sexual contact. After the adaptive introgression of Neanderthal-Denisovan alleles, anatomically modern humans on non-African ancestry carry nowadays in average between 2-4% of their genomes of archaic human origin (Meyer et al. 2012; Prüfer et al. 2014). Remarkably, the horizontal transfer of genetic loci upon interbreeding of Neanderthal/Denisovan ancestry into the genome of modern human ancestors did not occur at random (Vernot and Akey 2014; Kuhlwilm et al. 2016; Vernot et al. 2016). Instead, genes involved in keratinocyte differentiation and innate immunity, which are loci directly involved in host-PV interaction, are particularly enriched in introgressed genomic loci, displaying above 60% of Neanderthal/Denisovan ancestry in present day Eurasians (table 6) (Abi-Rached et al. 2011; Sankararaman et al. 2014; Vernot and Akey 2014; Vernot et al. 2016). Such genetic changes possibly altered the HPV16-human interplay, as this virus exclusively infects keratinocytes in particular epithelia and requires keratinocyte differentiation to accomplish the virus life cycle and virion production (Doorbar et al. 2012). Hence, we speculate that the adaptive introgression in modern humans of archaic alleles involved in keratinocyte differentiation and innate immunity may have elicited changes in the ecological niche of HPV16 that significantly enhanced the adaptive value of HPV16A and lead to increased prevalence of this viral lineage in modern human populations with Eurasian origin (figs. 2, 3BC, 4).

Taken together, our *HHS* evolutionary model provides explanatory potential for the three central flaws of the alternative *ROOA* scenario for the evolution of HPV16, namely i) the

distant phylogenetic relationship between HPV16A and HPV16BCD clades (fig. 1AB), which predates the most recent out-of-Africa migration of modern human ancestors (table 3); ii) the global increased prevalence of HPV16A outside Africa (fig. 2), and iii) the increased viral genetic diversity outside sub-Saharan Africa (table 4). In agreement with our *HHS* model, recent studies of parasites evolution have concluded that the divergence of at least five present day human parasites (lice, tapeworm, follicle mites, a protozoan and bedbug) predates modern human origin. The most likely explanation for the presence of these closely related ancient pairs of parasite taxa involves host switch from an archaic to modern human ancestors (Ashford 2000; Reed et al. 2004). Furthermore, evolutionary studies of sexually transmitted herpes simplex-virus suggest ancient codivergence and later cross-species transmission of this pathogen between ancestors of chimpanzees and extinct Hominin groups (Wertheim et al. 2014).

Despite the explanatory power of our results, our study suffers from a number of limitations. Ideally the global host and pathogen sequence data should be analysed at the level of full genomes from the same individuals, but such dataset is not available. Further, there is hitherto no evidence of the presence of any PV sequences from ancient human samples. Indeed, we analysed the currently available Neanderthal and Denisovan pre-assembly sequence data, and we could not find any significant traces of any known HPVs in these data sets. Unfortunately, the epithelial tropism of these viruses likely prevents retrieving viral sequences from fossil bones, the common reservoir for ancient DNA studies. We have also tried to identify sequence traces of PV DNA from the metagenomic sequence data extracted from tissue remains of the European Copper Age glacier mummy (Maixner et al. 2014) but could not find any traces of PV DNA in any of these sample datasets. However, future studies encompassing larger global sample of individuals with full human and HPV genome sequence data and/or well-preserved ancestral human samples containing PVs DNA will allow to test and refute or validate our hypothesis.

We have presented here the most comprehensive study of the evolution and diversity of HPV16, the most oncogenic infectious agent for humans. Our phylogeographic analyses confirm the limited contribution of virus-host codivergence to the evolution of the HPV16 lineage: most of the geography-based diversity within HPV16 cannot be explained alone by co-speciation with modern humans. Instead, our results suggest that ancestral HPV16 already infected the ancestor of *H. sapiens* and *H. neanderthalensis* half a million years ago, and that two main HPV16 lineages codiverged with either human lineage. When a population of

modern humans migrated out of Africa some 60–120kya, they carried with them a subset of the HPV16 diversity evolved in that continent. When modern humans encountered and interbred with Neanderthal/Denisovan populations in Europe and in Asia, a transfer of sexually transmitted pathogens occurred, in parallel with the genomic introgression. Gene alleles involved in keratinocyte differentiation and in innate immunity evolved among Neanderthals/Denisovans and transferred to modern humans, may have facilitated niche colonisation and expansion of HPV16A in modern human populations with archaic admixture. This evolutionary advantage led to the enhanced prevalence of HPV16A lineage among modern humans with introgressed archaic genetic background. Indeed, our results show that sexually transmitted pathogens may have been effectively transferred between different Hominin populations in recent events. We propose that the repertoire of the HPV16 variants co-evolved with archaic humans, the diversity of keratinocyte differentiation and innate immune genes that have undergone adaptive introgression, and eventually the interaction between viral and host genotypes may be largely responsible for the differential association of certain HPV16 variants with cancer risk in certain modern human populations.

MATERIALS AND METHODS

HPV16 complete genomes and partial sequences

The full genome sequences for 118 HPV16 isolates used for the analysis were retrieved from GenBank. Sequences were aligned with MUSCLE (Edgar 2004), at amino acid level for the coding region and at nucleotide level for the UTR, and tested for putative recombination break points using GARD algorithm (Kosakovsky Pond et al. 2006). The final full-genome alignment encompassed 118 full-length HPV16 genomes, 7926bp and 638 distinct alignment patterns (alignment available as supplementary data S1, supplementary material online). Best substitution model for the HPV16 full genome data, manually curated and filtered using Gblocks (Castresana 2000), was inferred using jModelTest 2.0 (Darriba et al. 2012). Phylogenetic inference was performed under maximum likelihood (ML) framework with RAxML v8.0.16 using the general time-reversible model of nucleotide substitution with Γ -rate heterogeneity parameter (GTR+ Γ_4) and 500 bootstrap replicates (Stamatakis 2014). Besides the unpartitioned analysis, four partition schemes were also explored: i) partitions of non-coding and coding regions; ii) the same as before, but further partitioning the coding region into three codon positions; iii) eight partitions corresponding to the regulatory region and to the *E6*, *E7*, *E1*, *E2*, *E5*, *L2*, *L1* genes; iv) the same as before, but further partitioning each coding regions

into three codon positions. Among all partition schemes explored, the unpartitioned scheme rendered the best AIC scores.

In order to focus on the HPV16 genome positions evolving under neutrality and to filter out the possible bias arising from the presence of positions undergoing natural selection, we identified and removed a total of 26 positively selected and 115 negatively selected codons from the full genome alignment (supplementary table S1, supplementary material online). Each coding region of the HPV16 genome was separately assessed for codon-based selection using random effects likelihood (REL) model with ML fit (Pond and Muse 2005) and Bayes Factor of 20 (*i.e.* p -value=0.05) as a level of significance, except the *L2* gene region, which was assessed for selection using maximum likelihood reconstruction of ancestral codons with a p -value=0.05 as a level of significance, due to computational limitations of the REL model with the *L2* alignment (Kosakovsky Pond and Frost 2005). The final coding region alignment manually curated and filtered for sites under selection, encompassed 118 HPV16 sequences, 6093bp and 316 distinct alignment patterns (alignment available as supplementary data S2, supplementary material online).

To define the root of the HPV16 complete genome ML tree, the five main lineages (*i.e.* A1-3, A4, B, C, D) were identified and the two most divergent members of each lineage were retained. These ten HPV16 variant genomes were aligned, separately for each *E1*, *E2*, *L2* and *L1* coding region, with the genomes of all other members of *Alphapapillomaviruses species 9*: HPV31, HPV33, HPV35, HPV52, HPV58, HPV67. The concatenated coding regions genome alignment was submitted to ML phylogenetic inference following the same protocol described above. The procedure was replicated using Bayesian inference with Phylobayes (Lartillot and Philippe 2004), both at the amino acid and at nucleotide level. The differential likelihood of our two alternative hypothesis for the location of the root in the HPV16 lineage for the root location in the HPVs, namely *ROOA* and *HHS* models, was further assessed using Shimodaira-Hasegawa (Shimodaira and Hasegawa 1989) and Robinson-Foulds comparison tests (Robinson and Foulds 1981).

Phylogenetic relationships of partial HPV16 sequences spanning the LCR, *E6* and *L2* loci from 1601 HPV16 isolates retrieved worldwide (supplementary table S6, supplementary material online) were placed in the genetic landscape of HPV16 complete genome variability using an Evolutionary Placement Algorithm on RAxML v8.0.16 with the *-f v* command and the GTR+ Γ_4 model (Berger and Stamatakis 2011). The algorithm provides likelihood weights for placing partial sequences into the different nodes in the reference tree (supplementary table S2,

supplementary material online), which in our case was the best ML tree obtained for the 118 complete HPV16 genomes (supplementary fig. 1, supplementary material online). Partial HPV16 sequences were introduced into the initial genome alignment using MAFFT (Katoh and Standley 2013). The final alignment consisted of 1719 isolates (118 complete genomes, 1082 isolates of 1338bp partial sequences spanning the LCR and *E6* loci and 519 isolates of 665bp partial sequences spanning the LCR, *E6* and *L2* loci, see available alignments in supplementary data S3-S4, supplementary material online). For each partial sequence, we integrated the likelihood weights for all nodes using 0.7 as a likelihood cut-off value to confidently assign each sample into one of the five main HPV16 variant lineages (supplementary table S2, supplementary material online). Finally, we stratified the HPV16 variant isolate data into ten geographical population groups: North/East/West/Southern Africa, South Asia, East Asia, Europe, Central and South America using the United Nations standard geographical criteria (supplementary table S3, supplementary material online). To compare the genetic variability patterns observed for HPV16 isolates within each geographic population group we calculated the summary statistics of the available 1123 HPV16 *E6* sequences (table 4). Further to visualize the genetic variability of the 1123 HPV16 *E6* 456bp nearly-complete gene sequences within each geographic background a haplotype-specific median joining network was constructed using NETWORK 4.6.1.3 (www.fluxus-technology.com) with equal weight for variable positions.

Bayesian MCMC inference

Evolutionary analysis for HPV16 lineages was estimated using both the complete 7926bp genome alignment and the selection-filtered 6093bp coding region alignment of 118 HPV16 variants (supplementary data S1-S2, supplementary material online), and using Bayesian Markov chain Monte Carlo (MCMC) analysis as implemented in BEAST v.1.8.1 (Drummond et al. 2012). Bayesian MCMC inferences were performed with the GTR+ Γ_4 model. Genealogies were estimated using both strict and relaxed molecular clocks with an uncorrelated log-normal distribution of rates. Two credible PVs substitution rate estimates from the literature were used as uniform priors: 9.6×10^{-9} [$5.5 \times 10^{-9} - 13.6 \times 10^{-9}$] subs/site/year (Shah et al. 2010) and 19.5×10^{-9} [$13.2 \times 10^{-9} - 24.7 \times 10^{-9}$] subs/site/year (Rector et al. 2007). We also assessed the suitability of two additional plausible substitution rates, namely the values inferred for mammalian genomes 2.2×10^{-9} [$2.0 \times 10^{-9} - 2.4 \times 10^{-9}$] subs/site/year (Kumar and Subramanian 2002) and for human mitochondrial genomes 25.3×10^{-9} [$17.6 \times 10^{-9} - 32.3 \times 10^{-9}$] subs/site/year (Fu et al. 2014). In addition, a non-informative uniform prior between $4.5 \times 10^{-11} - 4.5$

subs/site/year covering all plausible PVs rate for both molecular clock models was used (table 2). Two recently revised evolutionary time point estimates for human populations were used as prior normal distribution for calibration of the HPV16 variant phylogenetic tree (table 2 and fig. 3C): first, the archaic divergence of modern humans and Neanderthals/Denisovans was set at 500kya (95% confidence interval 400-600kya)(Reich et al. 2010; Scally and Durbin 2012; Buck and Stringer 2014; Mendez et al. 2016); second, modern humans migration out-of-Africa was set at 90kya (95% confidence interval 60 – 120kya)(Scally and Durbin 2012; Liu et al. 2015). All evolutionary related parameters were estimated with the following demographic models: i) constant population size, ii) exponential growth and iii) Bayesian skyline coalescent models (Pybus et al. 2000). Two independent runs were performed for each parameter combination with 100 million generations and subsampling every 10,000 generations. The resulting tree and log-files were combined for further analysis after removing a 10% burn-in from each run. Statistical confidence in parameter estimates was assessed by reporting marginal posterior means and their associated 95% highest probability density intervals (95% HPD). Efficient mixing of the chains in the Bayesian MCMC analysis was assessed with effective sample size values above 200 for all parameters. Convergence of each of the simulations was visually confirmed before data were merged for further analysis. The combined Bayesian phylogenetic inferences were analyzed using Tracer v.1.6 and TreeAnnotator v.1.8.1 and visualized using Figtree v.1.4.2. Best model estimates to explain the HPV16 variant diversity were selected using two independent path sampling runs with at least 1 million iterations per path step and until no significant changes were observed in log marginal likelihoods for Bayes Factor ($2\ln BF$) estimates (Baele et al. 2012; Baele et al. 2013) as implemented in BEAST v.1.8.1 (Drummond et al. 2012). The support of a particular model was assessed with $2\ln BF < 2$ indicating no support, $2\ln BF = 2-6$ indicating positive model support, $2\ln BF = 6-10$ indicating strong positive support and $2\ln BF > 10$ indicating definitive distinction between competing models.

To determine the best topology for the HPV16 viral lineages, the maximum clade credibility trees were also inferred for both complete and selection-filtered coding region HPV16 genome alignments, without imposing any prior on tree topology, using BEAST v.1.8.1 (Drummond et al. 2012), and further assessing the distance between the obtained trees using *K tree score* (Soria-Carrasco et al. 2007). Wilcoxon-Mann-Whitney test was used to determine the significance of intertaxa pairwise differences between the complete and selection filtered coding region HPV16 ML trees. Summary statistics, including Tajima's D, Fu's & Li's D* and R2 were calculated using DnaSP v.5.10.1. (Librado and Rozas 2009).

Human genome data

To compare the phylogeography of HPV16 with the global variability of the human genome we compiled human mitochondrial, Y chromosome and autosomal genotype data of the same 938 non-related individuals of the CEPH Human Genome Diversity Panel representing 51 human populations worldwide (Cann et al. 2002). In order to systematically compare the host and pathogen genome diversity distribution, we stratified the human population genetic data in nine subcontinental metapopulation groups (supplementary table S3, supplementary material online) using the same geographical classification presented for HPV16 isolate data in supplementary table S6 (supplementary material online). This geographical grouping of human population genetic data reflected, as far as possible, the metapopulation groups from which the viral isolates were sampled. All mitochondrial complete genome sequences were manually aligned using MUSCLE (Edgar 2004) and 875 complete mtDNA genomes available from (Lippold et al. 2014) were used in this study. Y chromosome non-recombining region sequences from 551 males were retrieved (Lippold et al. 2014) and all variable loci data were included in this study. Autosomal single nucleotide polymorphism (SNP) loci data ascertained using either a European or sub-Saharan African individual as previously reported (Reich et al. 2010) were used in this study. All autosomal SNP markers were previously genotyped in 934 CEPH diversity panel individuals (Green et al. 2010; Reich et al. 2010). The African and European ascertained data sets consisted of 12,162 and 111,970 SNPs, respectively, covering all autosomal chromosomes of the human genome. All autosomal SNP genotype quality control and data mining were performed using PLINK software (Purcell et al. 2007). Only SNPs with $MAF > 0.01$ were used in further analysis. Phasing for each genotype data sets per chromosome were performed using BEAGLE software (Browning and Browning 2007). Genetic F_{ST} distances (WRIGHT 1951) between the nine geographical population groups defined above, and excluding North America, were estimated for 1101 available HPV16 isolate sequences encompassing LCR (735bp) and E6 (457bp) genome regions (supplementary fig. S3, supplementary material online) as well as for each of the human genome marker data sets (mitochondrial, Y chromosome, and autosomal SNPs). Mantel's permutation test for matrix similarity was implemented for pairwise combinations of F_{ST} distance matrices with 10,000 permutations. To search for possible traces of HPVs, including all known HPV16 variants, in archaic humans we retrieved all available Neanderthal and Denisovan pre-assembly sequence data from <http://cdna.eva.mpg.de/neandertal/altai/AltaiNeandertal> and <http://www.ebi.ac.uk/ena/data/view/PRJEB3092>, respectively. Reads were mapped against all

known HPVs genomes using bowtie2 (version: 2.2.5) with *--very-sensitive* command for the alignment. Further details of data processing is available from the authors upon request.

AUTHORS' CONTRIBUTIONS

Designed and conceived the project: VNP, IGB. Retrieved data and performed the phylogenetic inference: VNP, CMO. Performed the modern and archaic human genome data analyses and Bayesian MCMC inference: VNP. Wrote the manuscript: VNP, IGB. All authors contributed to, read and approved the final manuscript.

ACKNOWLEDGEMENTS

This research was financially supported by The European Society of Clinical Microbiology and Infectious Diseases (ESCMID Research Grant 2015 VNP), Aaltonen Foundation (VNP), Otto A. Malmi Foundation (VNP), The São Paulo Research Foundation (FAPESP grant #2011/24035-2 and #2012/23290-1, CMO) and the European Research Council (Contract #647916, IGB). No agency had any role in the interpretation of the results or in the preparation of the manuscript. Alexander Herbig is warmly thanked for the help in the analysis of the metagenomic data of the European Copper Age glacier mummy. Xavier Bosch, Samuel Alizon and Yannis Michalakis are thanked for helpful comments and review of an initial version of the manuscript.

REFERENCES

- 1000 Genomes Project Consortium, Auton A, Brooks LD, Durbin RM, Garrison EP, Kang HM, Korbel JO, Marchini JL, McCarthy S, McVean GA, et al. 2015. A global reference for human genetic variation. *Nature* 526:68–74.
- Abi-Rached L, Jobin MJ, Kulkarni S, McWhinnie A, Dalva K, Gragert L, Babrzadeh F, Gharizadeh B, Luo M, Plummer F a, et al. 2011. The shaping of modern human immune systems by multiregional admixture with archaic humans. *Science* 334:89–94.
- Antonsson A, Karanfilovska S, Lindqvist PG, Hansson BG. 2003. General acquisition of human papillomavirus infections of skin occurs in early infancy. *J. Clin. Microbiol.* 41:2509–2514.
- Ashford RW. 2000. Parasites as indicators of human biology and evolution. *J. Med. Microbiol.* 49:771–772.
- Baele G, Lemey P, Bedford T, Rambaut A, Suchard MA, Alekseyenko A V. 2012. Improving the accuracy of demographic and molecular clock model comparison while accommodating

- phylogenetic uncertainty. *Mol. Biol. Evol.* 29:2157–2167.
- Baele G, Li WLS, Drummond AJ, Suchard MA, Lemey P. 2013. Accurate model selection of relaxed molecular clocks in bayesian phylogenetics. *Mol. Biol. Evol.* 30:239–243.
- Berger SA, Stamatakis A. 2011. Aligning short reads to reference alignments and trees. *Bioinformatics* 27:2068–2075.
- Bernard HU. 1994. Coevolution of papillomaviruses with human populations. *Trends Microbiol.* 2:140–143.
- Berumen J, Ordoñez RM, Lazcano E, Salmeron J, Galvan SC, Estrada RA, Yunes E, Garcia-Carranca A, Gonzalez-Lira G, Madrigal-de la Campa A. 2001. Asian-American variants of human papillomavirus 16 and risk for cervical cancer: a case-control study. *J. Natl. Cancer Inst.* 93:1325–1330.
- Bouvard V, Baan R, Straif K, Grosse Y, Secretan B, Ghissassi F El, Benbrahim-Tallaa L, Guha N, Freeman C, Galichet L, et al. 2009. A review of human carcinogens—Part B: biological agents. *Lancet Oncol.* 10:321–322.
- Bravo IG, Félez-Sánchez M. 2015. Papillomaviruses: Viral evolution, cancer and evolutionary medicine. *Evol. Med. public Heal.* 2015:32–51.
- Browning SR, Browning BL. 2007. Rapid and accurate haplotype phasing and missing-data inference for whole-genome association studies by use of localized haplotype clustering. *Am. J. Hum. Genet.* 81:1084–1097.
- Bruni L, Diaz M, Castellsagué X, Ferrer E, Bosch FX, de Sanjosé S. 2010. Cervical human papillomavirus prevalence in 5 continents: meta-analysis of 1 million women with normal cytological findings. *J. Infect. Dis.* 202:1789–1799.
- Buck LT, Stringer CB. 2014. *Homo heidelbergensis*. *Curr. Biol.* 24:R214–R215.
- Burk RD, Terai M, Gravitt PE, Brinton LA, Kurman RJ, Barnes WA, Greenberg MD, Hadjimichael OC, Fu L, McGowan L, et al. 2003. Distribution of human papillomavirus types 16 and 18 variants in squamous cell carcinomas and adenocarcinomas of the cervix. *Cancer Res.* 63:7215–7220.
- Bzhalava D, Eklund C, Dillner J. 2015. International standardization and classification of human papillomavirus types. *Virology* 476:341–344.
- Cann HM, de Toma C, Cazes L, Legrand M-F, Morel V, Piouffre L, Bodmer J, Bodmer WF, Bonne-Tamir B, Cambon-Thomsen A, et al. 2002. A human genome diversity cell line panel. *Science* 296:261–262.

- Castresana J. 2000. Selection of conserved blocks from multiple alignments for their use in phylogenetic analysis. *Mol. Biol. Evol.* 17:540–552.
- Chesson HW, Dunne EF, Hariri S, Markowitz LE. 2014. The estimated lifetime probability of acquiring human papillomavirus in the United States. *Sex. Transm. Dis.* 41:660–664.
- Cornet I, Gheit T, Franceschi S, Vignat J, Burk RD, Sylla BS, Tommasino M, Clifford GM. 2012. Human papillomavirus type 16 genetic variants: phylogeny and classification based on E6 and LCR. *J. Virol.* 86:6855–6861.
- Cornet I, Gheit T, Iannacone MR, Vignat J, Sylla BS, Del Mistro A, Franceschi S, Tommasino M, Clifford GM. 2013. HPV16 genetic variation and the development of cervical cancer worldwide. *Br. J. Cancer* 108:240–244.
- Darriba D, Taboada GL, Doallo R, Posada D. 2012. jModelTest 2: more models, new heuristics and parallel computing. *Nat. Methods* 9:772.
- Doorbar J, Quint W, Banks L, Bravo IG, Stoler M, Broker TR, Stanley MA. 2012. The Biology and Life-Cycle of Human Papillomaviruses. *Vaccine*:1–16.
- Drummond AJ, Suchard MA, Xie D, Rambaut A. 2012. Bayesian phylogenetics with BEAUti and the BEAST 1.7. *Mol. Biol. Evol.* 29:1969–1973.
- Edgar RC. 2004. MUSCLE: multiple sequence alignment with high accuracy and high throughput. *Nucleic Acids Res.* 32:1792–1797.
- Einstein MH, Schiller JT, Viscidi RP, Strickler HD, Coursaget P, Tan T, Halsey N, Jenkins D. 2009. Clinician’s guide to human papillomavirus immunology: knowns and unknowns. *Lancet. Infect. Dis.* 9:347–356.
- Freitas LB, Chen Z, Muqui EF, Boldrini NAT, Miranda AE, Spano LC, Burk RD. 2014. Human papillomavirus 16 non-European variants are preferentially associated with high-grade cervical lesions. *PLoS One* 9:e100746.
- Fu Q, Li H, Moorjani P, Jay F, Slepchenko SM, Bondarev AA, Johnson PLF, Aximu-Petri A, Prüfer K, de Filippo C, et al. 2014. Genome sequence of a 45,000-year-old modern human from western Siberia. *Nature* 514:445–449.
- García-Vallvé S, Alonso A, Bravo IG. 2005. Papillomaviruses: different genes have different histories. *Trends Microbiol.* 13:514–521.
- Gottschling M, Göker M, Stamatakis A, Bininda-Emonds ORP, Nindl I, Bravo IG. 2011. Quantifying the phylodynamic forces driving papillomavirus evolution. *Mol. Biol. Evol.* 28:2101–2113.

- Gottschling M, Stamatakis A, Nindl I, Stockfleth E, Alonso A, Bravo IG. 2007. Multiple evolutionary mechanisms drive papillomavirus diversification. *Mol. Biol. Evol.* 24:1242–1258.
- Green RE, Krause J, Briggs AW, Maricic T, Stenzel U, Kircher M, Patterson N, Li H, Zhai W, Fritz MH-Y, et al. 2010. A draft sequence of the Neandertal genome. *Science* 328:710–722.
- Ho L, Chan SY, Burk RD, Das BC, Fujinaga K, Icenogle JP, Kahn T, Kiviat N, Lancaster W, Mavromara-Nazos P. 1993. The genetic drift of human papillomavirus type 16 is a means of reconstructing prehistoric viral spread and the movement of ancient human populations. *J. Virol.* 67:6413–6423.
- Holmes EC. 2008. Evolutionary history and phylogeography of human viruses. *Annu. Rev. Microbiol.* 62:307–328.
- Hurles ME, Nicholson J, Bosch E, Renfrew C, Sykes BC, Jobling MA. 2002. Y chromosomal evidence for the origins of oceanic-speaking peoples. *Genetics* 160:289–303.
- Johnson KP, Adams RJ, Page RDM, Clayton DH. 2003. When do parasites fail to speciate in response to host speciation? *Syst. Biol.* 52:37–47.
- Kapusinszky B, Mulvaney U, Jasinska AJ, Deng X, Freimer N, Delwart E. 2015. Local virus extinctions following a host population bottleneck. *J. Virol.*
- Katoh K, Standley DM. 2013. MAFFT multiple sequence alignment software version 7: improvements in performance and usability. *Mol. Biol. Evol.* 30:772–780.
- Kosakovsky Pond SL, Frost SDW. 2005. Not so different after all: a comparison of methods for detecting amino acid sites under selection. *Mol. Biol. Evol.* 22:1208–1222.
- Kosakovsky Pond SL, Posada D, Gravenor MB, Woelk CH, Frost SDW. 2006. Automated phylogenetic detection of recombination using a genetic algorithm. *Mol. Biol. Evol.* 23:1891–1901.
- Kuhlwilm M, Gronau I, Hubisz MJ, de Filippo C, Prado-Martinez J, Kircher M, Fu Q, Burbano HA, Lalueza-Fox C, de la Rasilla M, et al. 2016. Ancient gene flow from early modern humans into Eastern Neanderthals. *Nature* 530:429–433.
- Kumar S, Subramanian S. 2002. Mutation rates in mammalian genomes. *Proc. Natl. Acad. Sci. U. S. A.* 99:803–808.
- Lartillot N, Philippe H. 2004. A Bayesian mixture model for across-site heterogeneities in the amino-acid replacement process. *Mol. Biol. Evol.* 21:1095–1109.

- Lazaridis I, Patterson N, Mitnik A, Renaud G, Mallick S, Kirsanow K, Sudmant PH, Schraiber JG, Castellano S, Lipson M, et al. 2014. Ancient human genomes suggest three ancestral populations for present-day Europeans. *Nature* 513:409–413.
- Librado P, Rozas J. 2009. DnaSP v5: a software for comprehensive analysis of DNA polymorphism data. *Bioinformatics [Internet]* 25:1451–1452. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/19346325>
- Lippold S, Xu H, Ko A, Li M, Renaud G, Butthof A, Schröder R, Stoneking M. 2014. Human paternal and maternal demographic histories: insights from high-resolution Y chromosome and mtDNA sequences. *Investig. Genet.* 5:13.
- Liu W, Martinón-Torres M, Cai Y, Xing S, Tong H, Pei S, Sier MJ, Wu X, Edwards RL, Cheng H, et al. 2015. The earliest unequivocally modern humans in southern China. *Nature* 526:696–699.
- Lopera EA, Baena A, Florez V, Montiel J, Duque C, Ramirez T, Borrero M, Cordoba CM, Rojas F, Pareja R, et al. 2014. Unexpected inverse correlation between Native American ancestry and Asian American variants of HPV16 in admixed Colombian cervical cancer cases. *Infect. Genet. Evol.* 28:339–348.
- López-Bueno A, Mavian C, Labella AM, Castro D, Borrego JJ, Alcami A, Alejo A. 2016. Concurrence of Iridovirus, Polyomavirus, and a Unique Member of a New Group of Fish Papillomaviruses in Lymphocystis Disease-Affected Gilthead Sea Bream. *J. Virol.* 90:8768–8779.
- Ma Y, Madupu R, Karaoz U, Nossa CW, Yang L, Yooseph S, Yachimski PS, Brodie EL, Nelson KE, Pei Z. 2014. Human papillomavirus community in healthy persons, defined by metagenomics analysis of human microbiome project shotgun sequencing data sets. *J. Virol.* 88:4786–4797.
- Maixner F, Thomma A, Cipollini G, Widder S, Rattei T, Zink A. 2014. Metagenomic analysis reveals presence of *Treponema denticola* in a tissue biopsy of the Iceman. *PLoS One* 9:e99994.
- Mendez FL, Poznik GD, Castellano S, Bustamante CD. 2016. The Divergence of Neandertal and Modern Human Y Chromosomes. *Am. J. Hum. Genet.* 98:728–734.
- Mendoza L, Picconi MA, Mirazo S, Mongelós P, Giménez G, Basiletti J, Arbiza J. 2013. Distribution of HPV-16 variants among isolates from Paraguayan women with different grades of cervical lesion. *Int. J. Gynecol. Obstet.* 122:44–47.

- Meyer M, Kircher M, Gansauge M-T, Li H, Racimo F, Mallick S, Schraiber JG, Jay F, Prüfer K, de Filippo C, et al. 2012. A high-coverage genome sequence from an archaic Denisovan individual. *Science* 338:222–226.
- Molden T, Feiring B, Ambur OH, Christiansen IK, Hansen M, Laake I, Meisal R, Myrvang E, Jonassen CM, Trogstad L. 2016. Human papillomavirus prevalence and type distribution in urine samples from Norwegian women aged 17 and 21 years: A nationwide cross-sectional study of three non-vaccinated birth cohorts. *Papillomavirus Res.*
- Moscicki A-B, Schiffman M, Burchell A, Albero G, Giuliano AR, Goodman MT, Kjaer SK, Palefsky J. 2012. Updating the natural history of human papillomavirus and anogenital cancers. *Vaccine* 30 Suppl 5:F24–F33.
- Picconi MA, Alonio LV, Sichero L, Mbayed V, Villa LL, Gronda J, Campos R, Teyssié A. 2003. Human Papillomavirus type-16 variants in Quechua aborigines from Argentina. *J. Med. Virol.* 69:546–552.
- Pond SK, Muse S V. 2005. Site-to-site variation of synonymous substitution rates. *Mol. Biol. Evol.* 22:2375–2385.
- Prüfer K, Racimo F, Patterson N, Jay F, Sankararaman S, Sawyer S, Heinze A, Renaud G, Sudmant PH, de Filippo C, et al. 2014. The complete genome sequence of a Neanderthal from the Altai Mountains. *Nature* 505:43–49.
- Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira MAR, Bender D, Maller J, Sklar P, de Bakker PIW, Daly MJ, et al. 2007. PLINK: a tool set for whole-genome association and population-based linkage analyses. *Am. J. Hum. Genet.* 81:559–575.
- Pybus OG, Rambaut A, Harvey PH. 2000. An integrated framework for the inference of viral population history from reconstructed genealogies. *Genetics* 155:1429–1437.
- Qin P, Stoneking M. 2015. Denisovan Ancestry in East Eurasian and Native American Populations. *Mol. Biol. Evol.* 32:2665–2674.
- Qmichou Z, Khyatti M, Berraho M, Ennaji MM, Benbacer L, Nejjari C, Benjaafar N, Benider A, Attaleb M, El Mzibri M. 2013. Analysis of mutations in the E6 oncogene of human papillomavirus 16 in cervical cancer isolates from Moroccan women. *BMC Infect. Dis.* 13:378.
- Rector A, Lemey P, Tachezy R, Mostmans S, Ghim S-J, Van Doorslaer K, Roelke M, Bush M, Montali RJ, Joslin J, et al. 2007. Ancient papillomavirus-host co-speciation in Felidae. *Genome Biol.* 8:R57.

- Reed DL, Smith VS, Hammond SL, Rogers AR, Clayton DH. 2004. Genetic analysis of lice supports direct contact between modern and archaic humans. *PLoS Biol.* 2:e340.
- Reich D, Green RE, Kircher M, Krause J, Patterson N, Durand EY, Viola B, Briggs AW, Stenzel U, Johnson PLF, et al. 2010. Genetic history of an archaic hominin group from Denisova Cave in Siberia. *Nature* 468:1053–1060.
- Robinson DF, Foulds LR. 1981. Comparison of phylogenetic trees. *Math. Biosci.* 53:131–147.
- Sankararaman S, Mallick S, Dannemann M, Prüfer K, Kelso J, Pääbo S, Patterson N, Reich D. 2014. The genomic landscape of Neanderthal ancestry in present-day humans. *Nature* 507:354–357.
- Sawyer S, Renaud G, Viola B, Hublin J-J, Gansauge MM-T, Shunkov M V., Derevianko AP, Prüfer K, Kelso J, Pa a bo S. 2015. Nuclear and mitochondrial DNA sequences from two Denisovan individuals. *Proc. Natl. Acad. Sci.* 112:2–6.
- Scally A, Durbin R. 2012. Revising the human mutation rate: implications for understanding human evolution. *13:745–753.*
- Schiffman M, Rodriguez AC, Chen Z, Wacholder S, Herrero R, Hildesheim A, Desalle R, Befano B, Yu K, Safaeian M, et al. 2010. A population-based prospective study of carcinogenic human papillomavirus variant lineages, viral persistence, and cervical neoplasia. *Cancer Res.* 70:3159–3169.
- Shah SD, Doorbar J, Goldstein RA. 2010. Analysis of host-parasite incongruence in papillomavirus evolution using importance sampling. *Mol. Biol. Evol.* 27:1301–1314.
- Sharp PM. 2002. Origins of Human Virus Diversity. *Cell* 108:305–312.
- Shimodaira H, Hasegawa M. 1989. Letter to the Editor Multiple Comparisons of Log-Likelihoods with Applications to Phylogenetic Inference. :1114–1116.
- Soria-Carrasco V, Talavera G, Igea J, Castresana J. 2007. The K tree score: quantification of differences in the relative branch length and topology of phylogenetic trees. *Bioinformatics* 23:2954–2956.
- Stamatakis A. 2014. RAxML version 8: a tool for phylogenetic analysis and post-analysis of large phylogenies. *Bioinformatics* 30:1312–1313.
- Stringer CB, Barnes I. 2015. Deciphering the Denisovans. *Proc. Natl. Acad. Sci. U. S. A.* 112:15542–15543.
- Tan SE, Garland SM, Rumbold AR, Zardawi I, Taylor-Thomson D, Condon JR, Tabrizi SN. 2013.

- Investigating a cluster of vulvar cancers in young women: Distribution of human papillomavirus and HPV-16 variants in vulvar dysplastic or neoplastic biopsies. *Sex. Health* 10:18–25.
- Vernot B, Akey JM. 2014. Resurrecting surviving Neandertal lineages from modern human genomes. *Science* 343:1017–1021.
- Vernot B, Akey JM. 2015. Complex History of Admixture between Modern Humans and Neandertals. *Am. J. Hum. Genet.* 96:448–453.
- Vernot B, Tucci S, Kelso J, Schraiber JG, Wolf AB, Gittelman RM, Dannemann M, Grote S, McCoy RC, Norton H, et al. 2016. Excavating Neandertal and Denisovan DNA from the genomes of Melanesian individuals. *Science*.
- Villa LL, Sichero L, Rahal P, Caballero O, Ferency A, Rohan T, Franco EL. 2000. Molecular variants of human papillomavirus types 16 and 18 preferentially associated with cervical neoplasia. *J Gen Virol* 81:2959–2968.
- Wertheim JO, Kosakovsky Pond SL. 2011. Purifying selection can obscure the ancient age of viral lineages. *Mol. Biol. Evol.* 28:3355–3365.
- Wertheim JO, Smith MD, Smith DM, Scheffler K, Kosakovsky Pond SL. 2014. Evolutionary origins of human herpes simplex viruses 1 and 2. *Mol. Biol. Evol.* 31:2356–2364.
- WRIGHT S. 1951. The genetical structure of populations. *Ann. Eugen.* 15:323–354.
- Xi LF, Kiviat NB, Hildesheim A, Galloway DA, Wheeler CM, Ho J, Koutsky LA. 2006. Human papillomavirus type 16 and 18 variants: race-related distribution and persistence. *J. Natl. Cancer Inst.* 98:1045–1052.
- Zuna RE, Tuller E, Wentzensen N, Mathews C, Allen RA, Shanesmith R, Dunn ST, Gold MA, Wang SS, Walker J, et al. 2011. HPV16 variant lineage, clinical stage, and survival in women with invasive cervical cancer. *Infect. Agent. Cancer* 6:19.

Figures and figure legends

Figure 1. Phylogenetic tree of the 118 HPV16 complete genomes. **A)** Unrooted maximum Likelihood phylogenetic tree inferred using the complete coding region alignment after excluding a total of 26 positively selected and 115 negatively selected codons. The final alignment encompassed 118 sequences, 6093bp and 316 distinct alignment patterns. Bootstrap support after 500 replicates is given for branches leading to the A1-3, A4, B, C and D variant lineages. Scale bar in substitutions per nucleotide site. **B)** Maximum clade credibility tree inferred for selection-filtered HPV16 genome coding region alignment under the *HHS* scenario, 9.6×10^{-9} [5.5×10^{-9} - 13.6×10^{-9}] subs/site/yr as substitution rate prior and enforcing two time point calibrations: archaic *Hominin* divergence at 500kya (95% confidence interval 400 – 600kya) and recent modern human migration out-of-Africa at 90kya (95% confidence interval 60 – 120kya). Scale bar in substitutions per nucleotide site and node bars indicate the 95% probability intervals for the corresponding node age.

Figure 2. Phylogeographic distribution of the 1680 HPV16 sequences encompassing the LCR, *E6* and *L2* genome loci. Each sequence was assigned to a specific HPV16 variant lineage (see the color coding for A1-3, A4, B, C and D variants). The size of the pie charts is proportional to the number of sequences from the corresponding geographic region (supplementary table S3, supplementary material online).

Figure 3. Timeline of divergence for archaic and modern human ancestors, and for HPV16. **A)** Dated and classification-confirmed Hominin fossil taxa [light green represents uncertain classification, as reviewed in (Scally and Durbin 2012)]. **B)** Phylogenetic relationship of modern human, Neanderthal and Denisovan populations. Vertical arrows indicate the proposed interbreeding and subsequent gene flow from the Neanderthal and Denisovan populations to the ancestors of present-day modern humans. The evolutionary relationships between Neanderthals and Denisovans are still unresolved (Sawyer et al. 2015; Stringer and Barnes 2015). **C)** Phylogenetic relationships for 118 selection-filtered HPV16 coding genome sequences using maximum clade credibility tree under the *Hominin host-switch* scenario. Blue bars indicate the 95% probability intervals for the corresponding node age. Arrows indicate the nodes used for calibration.

Figure 4. Cartoon timeline depicting interbreeding and subsequent gene flow of archaic alleles from Neanderthals and Denisovans into modern humans and the proposed sexual transmission of HPV16A lineage to the ancestors of modern human populations in Eurasia. Viral lineages HPV16A, B, C and D are labeled at the bottom.

Table 1. Mantel's permutation test for similarity of F_{ST} distance matrices between HPV16 and human genome sequence datasets.

Taxa	loci	region/ SNPs	N	Selection-filtered			Including positions under selection		
				Correlation (%) ^a	p-value ^b	FDR ^c	Correlation (%) ^a	p-value ^b	FDR ^c
mtDNA	1	16kb genome	875	12,4	0,037	0,017	15,8	0,026	0,018
NRY	1	5000kb	551	8,5	0,062	0,028	11,8	0,044	0,036
Europe	chr1	6353	773	8,8	0,062	0,029	12,7	0,033	0,026
Europe	chr2	5918	773	6,3	0,091	0,040	9,6	0,054	0,040
Europe	chr3	5325	773	8,8	0,063	0,032	12,7	0,037	0,030
Europe	chr4	4211	773	8,9	0,063	0,030	12,7	0,036	0,029
Europe	chr5	4743	773	5,6	0,104	0,047	8,7	0,061	0,047
Europe	chr6	4736	773	6,3	0,095	0,041	9,5	0,055	0,042
Europe	chr7	4162	773	5,2	0,112	0,048	8,1	0,062	0,048
Europe	chr8	3750	773	8,0	0,070	0,036	11,6	0,045	0,037
Europe	chr9	3222	773	8,8	0,064	0,033	12,7	0,038	0,033
Europe	chr10	4223	773	9,2	0,059	0,026	13,1	0,035	0,028
Europe	chr11	3850	773	5,9	0,099	0,046	9,2	0,058	0,046
Europe	chr12	3339	773	5,1	0,116	0,049	8,0	0,066	0,049
Europe	chr13	2234	773	5,8	0,098	0,045	9,2	0,057	0,045
Europe	chr14	2307	773	5,9	0,097	0,043	9,3	0,056	0,043
Europe	chr15	2346	773	6,2	0,096	0,042	9,3	0,054	0,041
Europe	chr16	2636	773	7,5	0,078	0,038	11,1	0,045	0,038
Europe	chr17	2109	773	6,8	0,084	0,039	10,1	0,045	0,039
Europe	chr18	2243	773	9,8	0,056	0,025	13,9	0,033	0,025
Europe	chr19	1175	773	3,9	0,139	0,050	6,5	0,085	0,050
Europe	chr20	2067	773	9,9	0,055	0,023	13,8	0,031	0,021
Europe	chr21	973	773	10,0	0,055	0,024	14,1	0,031	0,022
Europe	chr22	1141	773	7,7	0,073	0,037	11,6	0,042	0,034

HPV16 sequence data (1192bp) encompassing LCR (735bp) and *E6* (457bp) regions for 1101 worldwide isolates were used in the correlations. Mitochondrial DNA (mtDNA); Non-recombining part of the Y chromosome (NRY); Autosomal SNP data stratified by chromosome and ascertained using a European

(Europe) ancestry data (autosomal SNP data ascertained using a sub-Saharan ancestry data is provided in supplementary table S8, supplementary material online). For both datasets nine geographic metapopulations were defined: North/East/West/Southern Africa, South Asia, East Asia, Europe, Central and South America (supplementary table S2 and S5, supplementary material online).

^a R² of the correlation coefficient.

^b Mantel-test after 10, 000 permutations.

^c False discovery rate controlling procedure (q = 0.05).

Table 2. Substitution rate and divergence time estimates in thousands of years ago (kya) inferred for HPV16 complete (full) or selection-filtered genome alignment (neutral), under the *Hominin host-switch* (HHS) or the *Recent Out-of-Africa* (ROOA) scenarios, and considering different priors. Likelihood values in bold are the best-supported models, taken as reference (ref) for the path sampling Bayes factor (2lnBF) comparison.

Model	calibration	rate uniform prior		data	$\times 10^{-9}$ (subst./site/yr)			log marginal likelihood	2lnBF	tmrca ABCD (kya)			tmrca A1-4 (kya)			tmrca BCD (kya)			tmrca CD (kya)						
		$\times 10^{-9}$ (subst./site/year)	μ		(95% HPD)					mean	(95% HPD)	mean	(95% HPD)	mean	(95% HPD)	mean	(95% HPD)	mean	(95% HPD)						
HHS	HHS 2 calib	PVs estimate[13.2-24.7] ^a	neutral	18,4	14,5	-	22,1	-12476,94	ref	461	365	-	561	87	48	-	133	197	121	-	293	105	82	-	129
HHS	HHS 2 calib	human mtDNA [17.6-32.3] ^b	neutral	20,3	16	-	25,1	-12480,34	6,8	456	358	-	553	78	42	-	123	184	109	-	273	101	76	-	124
HHS	HHS 2 calib	PVs estimate [5.5-13.6] ^c	neutral	12,8	11,1	-	14,3	-12484,91	15,9	484	396	-	580	130	80	-	190	250	158	-	360	122	100	-	144
HHS	HHS 2 calib	mammal genome [2.0-2.4] ^d	neutral	3,6	3,1	-	4,1	-12567,19	180,5	571	488	-	655	423	284	-	578	408	267	-	575	180	158	-	201
HHS	HHS 2 calib	4.5-4.5E-11	neutral	20,2	14,0	-	26,8	-12482,18	10,5	457	357	-	555	79	40	-	128	185	105	-	280	101	75	-	128
HHS	HHS 1 calib 500kya	4.5-4.5E-11	neutral	13,6	8,1	-	20,3	-12482,41	10,9	490	389	-	587	125	55	-	206	311	157	-	471	197	95	-	312
HHS	HHS 1 calib 90kya	4.5-4.5E-11	neutral	32,1	17,0	-	49,6	-12483,21	12,5	210	92	-	346	54	23	-	91	134	72	-	203	85	53	-	115
ROOA	90kya	4.5-4.5E-11	neutral	80,5	40,3	-	128	-12481,41	8,9	85	54	-	115	22	9	-	38	54	24	-	87	34	14	-	56
HHS	HHS 2 calib	PVs estimate[13.2-24.7] ^a	full	22,9	20,3	-	25,3	-19313,69	4,7	476	387	-	568	147	101	-	200	246	164	-	343	127	106	-	148
HHS	HHS 2 calib	human mtDNA [17.6-32.3] ^b	full	27,5	23,5	-	31,0	-19311,33	ref	459	364	-	551	120	79	-	166	216	140	-	300	116	95	-	138
HHS	HHS 2 calib	PVs estimate [5.5-13.6] ^c	full	14,4	13,1	-	15,8	-19333,81	44,9	519	431	-	607	240	167	-	324	330	212	-	455	152	131	-	173
HHS	HHS 2 calib	mammal genome [2.0-2.4] ^d	full	4,6	4,0	-	5,2	-19502,91	383,1	650	571	-	727	616	518	-	705	411	320	-	498	214	189	-	232
HHS	HHS 2 calib	4.5-4.5E-11	full	33,9	24,4	-	43,4	-19314,23	5,8	446	346	-	544	95	53	-	142	186	110	-	271	105	80	-	132
HHS	HHS 1 calib 500kya	4.5-4.5E-11	full	22,0	13,2	-	31,2	-19311,87	1,1	490	390	-	586	156	78	-	240	320	176	-	473	209	111	-	319
HHS	HHS 1 calib 90kya	4.5-4.5E-11	full	55,0	31,8	-	82,9	-19311,82	1	199	99	-	322	63	31	-	100	130	73	-	193	84	54	-	115
ROOA	90kya	4.5-4.5E-11	full	130,6	71,8	-	206,0	-19311,94	1,2	84	54	-	115	27	12	-	44	55	27	-	88	36	17	-	58

^a (Rector et al. 2007), ^b (Fu et al. 2014), ^c (Shah et al. 2010) and ^d (Kumar and Subramanian 2002).

Table 3. Substitution rate and divergence time estimates in thousands of years ago (kya) inferred for HPV16 complete (full) or selection-filtered genome alignment (neutral) either under the HHS scenario or without imposing any prior on tree topology, and without using any time point calibrations, and using instead only substitution rate priors.

Data	Model	calibration	uniform prior		x10 ⁻⁹ (subst./site/yr)			tmrca ABCD (kya)			tmrca A1-4 (kya)			tmrca BCD (kya)			tmrca CD (kya)		
			x10 ⁻⁹ (subst./site/year)	μ	95% HPD	mean	95% HPD	mean	95% HPD	mean	95% HPD	mean	95% HPD	mean	95% HPD	mean	95% HPD		
full	No topology	no calib		18.0	12.5 - 23.8	581	298 - 911	188	109 - 278	391	221 - 589	261	146 - 392						
neutral	No topology	no calib	PVs estimate[13.2-24.7] ^a	18.2	12.4 - 24.4	340	168 - 573	90	46 - 141	231	121 - 355	156	83 - 247						
neutral	HHS	no calib		18.2	12.4 - 24.2	361	178 - 592	92	50 - 147	228	123 - 353	145	81 - 222						
full	No topology	no calib		23.6	16.4 - 31.1	440	223 - 693	142	85 - 214	296	167 - 442	198	112 - 296						
neutral	No topology	no calib	human mtDNA [17.6-32.3] ^b	24.0	16.4 - 31.7	258	124 - 420	68	37 - 107	175	94 - 269	118	61 - 186						
neutral	HHS	no calib		23.9	16.4 - 31.6	273	136 - 444	70	37 - 108	173	95 - 271	110	60 - 167						
full	No topology	no calib		9.0	5.2 - 12.8	1181	532 - 2037	384	201 - 627	803	400 - 1330	536	267 - 870						
neutral	No topology	no calib	PVs estimate [5.5-13.6] ^c	9.1	5.2 - 13.2	698	296 - 1228	185	85 - 313	185	86 - 312	317	145 - 539						
neutral	HHS	no calib		9.1	5.2 - 13.1	742	324 - 1297	189	90 - 320	469	220 - 791	298	141 - 493						
full	No topology	no calib		2.1	1.8 - 2.4	4819	2914 - 7086	1564	1077 - 2133	3249	2108 - 4458	2177	1466 - 3015						
neutral	No topology	no calib	mammal genome [2.0-2.4] ^d	2.1	1.8 - 2.5	2863	1576 - 4415	755	457 - 1086	1919	1206 - 2741	1301	784 - 1916						
neutral	HHS	no calib		2.1	1.8 - 2.4	3010	1686 - 4582	767	475 - 1123	1900	1187 - 2738	1208	761 - 1691						

^a (Rector et al. 2007), ^b (Fu et al. 2014), ^c (Shah et al. 2010) and ^d (Kumar and Subramanian 2002).

Table 4. Summary statistics of the HPV16 *E6* gene sequences (N=1123) with geographic origin of the sample.

Metapopulation	N	bp	S	h	Hd	(95% CI) ^a	(95% CI) ^b	MPD	(95% CI) ^a	(95% CI) ^b	WIMP	Tajima's D	p-value ^c	(95% CI) ^b	p-value ^c	Fu's-Li's D*	(95% CI) ^b	p-value ^b	R2	(95% CI) ^b	p-value ^b
sub-Saharan Africa	213	456	34	32	0,754	(0,712-0,796)	(0,439-0,892)	3,049	(2,739-3,359)	(0,815-7,389)	1,459	-1,427	> 0,1	(-1,642-2,053)	0,047	-3,459	(-2,178-1,523)	0,003	0,044	(0,033-0,148)	0,100
North Africa	221	456	30	26	0,861	(0,839-0,883)	(0,653-0,918)	4,985	(4,52-5,45)	(1,543-12,592)	0,969	-0,196	> 0,1	(-1,598-2,097)	0,519	-3,288	(-1,959-1,311)	0,466	0,081	(0,035-0,14)	0,533
Europe	161	456	31	25	0,734	(0,688-0,78)	(0,16-0,838)	1,62	(1,401-1,839)	(0,194-4,219)	1,187	-2,043	< 0,05	(-1,62-2,05)	0,001	-3,825	(-1,958-1,447)	0,002	0,026	(0,028-0,164)	0,017
South Asia	139	456	8	6	0,523	(0,455-0,591)	(0,056-0,797)	0,998	(0,831-1,165)	(0,043-2,744)	0,464	-0,724	> 0,1	(-1,509-2,026)	0,253	-0,454	(-2,302-1,297)	0,281	0,062	(0,026-0,193)	0,302
East Asia	207	456	31	37	0,643	(0,567-0,719)	(0,495-0,894)	3,425	(3,079-3,771)	(0,853-8,014)	1,712	1,211	> 0,1	(-1,593-2,11)	0,091	-2,848	(-2,415-1,606)	0,014	0,054	(0,032-0,146)	0,180
Central America	50	456	21	14	0,889	(0,851-0,927)	(0,589-0,925)	4,551	(3,641-5,461)	(1,197-10,979)	1,803	-0,237	> 0,1	(-1,683-2,033)	0,475	-1,027	(-2,568-1,511)	0,167	0,103	(0,052-0,177)	0,503
South America	132	402	18	17	0,78	(0,744-0,816)	(0,486-0,893)	3,184	(2,774-3,594)	(0,772-7,859)	0,947	-0,096	> 0,1	(-1,613-1,896)	0,526	-0,850	(-2,371-1,543)	0,185	0,087	(0,035-0,156)	0,542

Downloaded from <http://mbe.oxfordjournals.org/> by guest on October 20, 2016

Number of samples (N), base pair (bp), Segregating sites (S), haplotypes (h), haplotype diversity (Hd), Mean pairwise difference (MPD), weighted intralineage mean pairwise difference (WIMP) (Hurles et al. 2002), Tajima's D, Fu's and Li's D* and R2 statistics were calculated using DnaSP (Librado and Rozas 2009).

^a calculated from empirical distribution.

^b calculated from a coalescent simulation with 1000 replications and no recombination.

^c calculated assuming beta distribution.

Table 5. HPV16 *E6* gene major haplotype frequencies within each lineage and geographical background.

Origin	A1-3 ^a		A1-3 ^b		A4		B		C		D	
	N	%	N	%	N	%	N	%	N	%	N	%
America	50	19.5	40	19.0	2	1.5	1	1.2	4	2.6	45	57.7
Eurasia	177	68.9	118	56.2	127	98.5	1	1.2	7	5.0	26	33.3
North Africa	27	10.5	46	21.9	-	-	4	4.7	53	37.6	4	5.0
Sub-Saharan Africa	3	1.2	6	2.9	-	-	79	92.9	77	54.6	3	3.8
											22	57.9
												2.6

^a Major haplotype including HPV16 *E6* 350G allele.

^b Major haplotype including HPV16 *E6* 350T allele.

Table 6. Global prevalence of HPV16A lineages (upper panel) and proportion of non-randomly introgressed archaic alleles into modern human ancestors (lower panel). A selection of host's genome loci is listed, directly involved in the Papillomavirus life-cycle through keratinocyte differentiation and innate immunity.

Human papillomavirus 16A lineages	Geography			Ref.
	sub-Saharan Africa	West Eurasia	East Eurasia	
HPV16A1-3	< 5%	93%	25-91%	this study
HPV16A4	absent	~ 1%	60%	this study
Host's genome loci directly involved in PVs life-cycle				
Neanderthal ancestry loci	absent	64%	62%	(Sankararaman et al. 2014)
Loci involved in keratinocyte differentiation	absent	40%-70%	40%-66%	(Vernot and Waller, 2014)
HLA I loci (innate immunity)	< 7%	52%-59%	72%-82%	(Abi-Rached et al. 2011)
Toll-like receptor loci (innate immunity)	absent	15%-39%	17%-51%	(Dannemann et al. 2015)
APOBEC3A deletion (innate immunity)	< 1%	7%	14-93%	(Kidd et al. 2007)




Figure 1. Phylogenetic tree of the 118 HPV16 variant complete genomes after excluding sites under positive or negative selection. B) Maximum clade credibility tree inferred for selection-filtered HPV16 genome coding region alignment.




Figure 2. Phylogeographic distribution of the 1680 HPV16 sequences encompassing the LCR, *E6* and *L2* genome loci.




Figure 3. Timeline of divergence for the archaic and modern human ancestors and HPV16.




Figure 4. Cartoon timeline depicting interbreeding and subsequent gene flow of archaic alleles from Neanderthals and Denisovans into modern humans and the proposed sexual transmission of HPV16A lineage to the ancestors of modern human populations in Eurasia.